Jacobson Pharma Yönetim
Yönetim kriter kontrolleri 1/4
We currently do not have sufficient information about the CEO.
Anahtar bilgiler
Derek Sum
İcra Kurulu Başkanı
HK$20.8m
Toplam tazminat
| CEO maaş yüzdesi | 19.6% |
| CEO görev süresi | 8.8yrs |
| CEO sahipliği | 60.2% |
| Yönetim ortalama görev süresi | Veri yok |
| Yönetim Kurulu ortalama görev süresi | 8.6yrs |
Son yönetim güncellemeleri
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Recent updates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2024 | HK$21m | HK$4m | HK$186m |
| Dec 31 2023 | n/a | n/a | HK$221m |
| Sep 30 2023 | n/a | n/a | HK$217m |
| Jun 30 2023 | n/a | n/a | HK$234m |
| Mar 31 2023 | HK$14m | HK$3m | HK$175m |
| Dec 31 2022 | n/a | n/a | HK$207m |
| Sep 30 2022 | n/a | n/a | HK$203m |
| Jun 30 2022 | n/a | n/a | HK$190m |
| Mar 31 2022 | HK$5m | HK$3m | HK$178m |
| Dec 31 2021 | n/a | n/a | HK$166m |
| Sep 30 2021 | n/a | n/a | HK$154m |
| Jun 30 2021 | n/a | n/a | HK$164m |
| Mar 31 2021 | HK$5m | HK$4m | HK$174m |
| Dec 31 2020 | n/a | n/a | HK$183m |
| Sep 30 2020 | n/a | n/a | HK$191m |
| Jun 30 2020 | n/a | n/a | HK$203m |
| Mar 31 2020 | HK$5m | HK$4m | HK$214m |
| Sep 30 2019 | n/a | n/a | HK$273m |
| Jun 30 2019 | n/a | n/a | HK$259m |
| Mar 31 2019 | HK$5m | HK$4m | HK$245m |
| Dec 31 2018 | n/a | n/a | HK$235m |
| Sep 30 2018 | n/a | n/a | HK$219m |
| Jun 30 2018 | n/a | n/a | HK$211m |
| Mar 31 2018 | HK$6m | HK$4m | HK$202m |
Tazminat ve Piyasa: Derek's total compensation ($USD2.67M) is above average for companies of similar size in the Hong Kong market ($USD359.95K).
Tazminat ve Kazançlar: Derek's compensation has increased by more than 20% in the past year.
CEO
Derek Sum (61 yo)
8.8yrs
Görev süresi
HK$20,779,000
Tazminat
Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 8.8yrs | HK$20.78m | 60.18% HK$ 762.6m | |
| VP of Administration & Executive Director | 7.8yrs | HK$3.18m | 0.42% HK$ 5.3m | |
| Executive Director | 8.6yrs | HK$6.77m | 2.04% HK$ 25.9m | |
| Independent Non-Executive Director | 8.6yrs | HK$230.00k | Veri yok | |
| Independent Non-Executive Director | 8.3yrs | HK$230.00k | Veri yok | |
| Member of Scientific Advisory Committee | 8.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Committee | 8.6yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Committee | 8.6yrs | Veri yok | Veri yok | |
| Non-Executive Director & Member of Scientific Advisory Committee | 8.6yrs | HK$230.00k | Veri yok | |
| Independent Non-Executive Director | 8.3yrs | HK$230.00k | 0.030% HK$ 384.0k |
8.6yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 2633's board of directors are considered experienced (8.6 years average tenure).